Although the exact mechanism underlying CNV development has not been fully elucidated, vascular endothelial growth factor (VEGF) plays a vital role in the process of CNV [4], and anti‐VEGF agents can be used to ameliorate the clinical outcomes of wet AMD patients. This evidence concerns the gene VEGFA and wet macular degeneration.